第五批**非遗传承人名单来了,中医药领域58名传承人入选!

2018-05-24 栗 征 中国中医

为加强非物质文化遗产传承人队伍建设,推动国家级非物质文化遗产代表性项目传承发展,文化和旅游部近日确定并公布了第五批国家级非物质文化遗产代表性项目代表性传承人名单,全国共1082名传承人入选,吴以岭、严慰冰等58名中医药非遗项目代表性传承人在列。他们的中医络病诊疗方法和古本易筋经十二势导引法作为中医诊疗法项目入选,其他中医药非遗项目还包括中药炮制技艺、中医传统制剂方法、针灸、中医正骨疗法、藏医药、蒙

为加强非物质文化遗产传承人队伍建设,推动国家级非物质文化遗产代表性项目传承发展,文化和旅游部近日确定并公布了第五批国家级非物质文化遗产代表性项目代表性传承人名单,全国共1082名传承人入选,吴以岭、严慰冰等58名中医药非遗项目代表性传承人在列。他们的中医络病诊疗方法和古本易筋经十二势导引法作为中医诊疗法项目入选,其他中医药非遗项目还包括中药炮制技艺、中医传统制剂方法、针灸、中医正骨疗法、藏医药、蒙医药、瑶族医药、苗医药、回族医药、维吾尔医药、哈萨克族医药等。

目前国务院已公布4批1372个国家级代表性项目,包含3154个子项。第五批国家级非物质文化遗产代表性项目代表性传承人认定主要关注三个方面:一是国务院新公布的第四批国家级代表性项目;二是前三批中无国家级代表性传承人的项目;三是现有国家级代表性传承人已去世的项目。

据悉,在这次评审工作中,文化和旅游部建立了专家组初评、评审委员会审议和社会公示等工作制度,确保评审工作公开、公平、公正。在评审专家组确定推荐名单后,评审委员会将推荐名单向社会进行了为期20天的公示,并严谨细致地核实了公示反馈意见,最终形成了第五批国家级代表性传承人入选名单。

国家级非物质文化遗产代表性项目代表性传承人是非物质文化遗产的重要承载者和传递者,掌握着非物质文化遗产的丰富知识和精湛技艺,是非物质文化遗产活态传承的代表性人物。文化和旅游部要求各地区、各部门要按照《中华人民共和国非物质文化遗产法》的规定,鼓励和支持非物质文化遗产代表性项目代表性传承人开展传承传播活动,切实做好非物质文化遗产保护传承工作,努力推动中华优秀传统文化创造性转化和创新性发展。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1928387, encodeId=3e1a192838ecc, content=<a href='/topic/show?id=ce7c3539270' target=_blank style='color:#2F92EE;'>#医药领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35392, encryptionId=ce7c3539270, topicName=医药领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Apr 25 00:53:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675585, encodeId=fa7c16e558538, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Fri Jul 06 19:53:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409539, encodeId=a1171409539bc, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat May 26 02:53:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318145, encodeId=c0b53181458b, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Thu May 24 12:02:15 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1928387, encodeId=3e1a192838ecc, content=<a href='/topic/show?id=ce7c3539270' target=_blank style='color:#2F92EE;'>#医药领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35392, encryptionId=ce7c3539270, topicName=医药领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Apr 25 00:53:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675585, encodeId=fa7c16e558538, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Fri Jul 06 19:53:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409539, encodeId=a1171409539bc, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat May 26 02:53:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318145, encodeId=c0b53181458b, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Thu May 24 12:02:15 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
    2018-07-06 lishizhe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1928387, encodeId=3e1a192838ecc, content=<a href='/topic/show?id=ce7c3539270' target=_blank style='color:#2F92EE;'>#医药领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35392, encryptionId=ce7c3539270, topicName=医药领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Apr 25 00:53:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675585, encodeId=fa7c16e558538, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Fri Jul 06 19:53:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409539, encodeId=a1171409539bc, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat May 26 02:53:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318145, encodeId=c0b53181458b, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Thu May 24 12:02:15 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
    2018-05-26 cathymary
  4. [GetPortalCommentsPageByObjectIdResponse(id=1928387, encodeId=3e1a192838ecc, content=<a href='/topic/show?id=ce7c3539270' target=_blank style='color:#2F92EE;'>#医药领域#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35392, encryptionId=ce7c3539270, topicName=医药领域)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=07f7192, createdName=waiwai3030, createdTime=Thu Apr 25 00:53:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675585, encodeId=fa7c16e558538, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Fri Jul 06 19:53:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409539, encodeId=a1171409539bc, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat May 26 02:53:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318145, encodeId=c0b53181458b, content=优质资源.共同学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K0LqDY57Aia0TOQByoJhNt3icm4sfukp500hLH6RHOpFdV01NbECtAV7s0qKpQPibyRukQAwAmqJU3X/0, createdBy=f91f1928792, createdName=九九消寒, createdTime=Thu May 24 12:02:15 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
    2018-05-24 九九消寒

    优质资源.共同学习

    0